Healthy volunteers to test new drug BCD-261 in Early-Stage safety trial
Knowledge-focused
Not yet recruiting
This early-stage study will test the safety of a single injection of BCD-261 in 48 healthy Chinese adults aged 18 to 45. Researchers will monitor for side effects and how the body processes the drug. The goal is to gather safety information, not to treat any disease.
Phase: PHASE1 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC